Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR11896(B)] to ATP1A2
- Suitable for: WB
- Reacts with: Mouse, Rat, Human
Product nameAnti-ATP1A2 antibody [EPR11896(B)]
See all ATP1A2 primary antibodies
DescriptionRabbit monoclonal [EPR11896(B)] to ATP1A2
Tested applicationsSuitable for: WBmore details
Unsuitable for: ICC/IF,IHC-P or IP
Species reactivityReacts with: Mouse, Rat, Human
Synthetic peptide corresponding to residues in Human ATP1A2 (P50993).
- Human skeletal muscle and fetal heart lysates
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Storage bufferPreservative: 0.01% Sodium azide
Constituents: 9% PBS, 40% Glycerol, 0.05% BSA, 50% Tissue culture supernatant
Concentration information loading...
PurityTissue culture supernatant
Our Abpromise guarantee covers the use of ab166888 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000 - 1/5000. Detects a band of approximately 102 kDa (predicted molecular weight: 112 kDa).|
FunctionThis is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates the electrochemical gradient of sodium and potassium, providing the energy for active transport of various nutrients.
Involvement in diseaseDefects in ATP1A2 are the cause of migraine familial hemiplegic type 2 (FHM2) [MIM:602481]. FHM2 is a rare, severe, autosomal dominant subtype of migraine characterized by aura and some hemiparesis.
Defects in ATP1A2 are a cause of alternating hemiplegia of childhood (AHC) [MIM:104290]. AHC is typically distinguished from familial hemiplegic migraine by infantile onset of the symptoms and high prevalence of associated neurological deficits that become increasingly obvious with age.
Sequence similaritiesBelongs to the cation transport ATPase (P-type) (TC 3.A.3) family. Type IIC subfamily.
Cellular localizationMembrane. Cell membrane.
- Information by UniProt
- AT1A2_HUMAN antibody
- Atp1a2 antibody
- FHM2 antibody
All lanes : Anti-ATP1A2 antibody [EPR11896(B)] (ab166888) at 1/1000 dilution
Lane 1 : Human skeletal
Lane 2 : Fetal heart lysate
Lysates/proteins at 10 µg per lane.
All lanes : HRP labelled goat anti-rabbit at 1/2000 dilution
Predicted band size: 112 kDa
Observed band size: 102 kDa why is the actual band size different from the predicted?
ab166888 has been referenced in 2 publications.
- Krohn M et al. Generation and Characterization of an Abcc1 Humanized Mouse Model (hABCC1flx/flx ) with Knockout Capability. Mol Pharmacol 96:138-147 (2019). PubMed: 31189668
- Srisomboon Y et al. P2Y receptor regulation of K2P channels that facilitate K+ secretion by human mammary epithelial cells. Am J Physiol Cell Physiol 314:C627-C639 (2018). PubMed: 29365273